

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Keisha Douglas

Timestamp: [year=2008; month=8; day=25; hr=16; min=57; sec=56; ms=443;]

=====

Application No: 10533103 Version No: 2.0

Input Set:

Output Set:

Started: 2008-07-23 11:22:48.409
Finished: 2008-07-23 11:22:49.026
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 617 ms
Total Warnings: 6
Total Errors: 0
No. of SeqIDs Defined: 14
Actual SeqID Count: 14

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)

SEQUENCE LISTING

<110> National Institutes of Health
Bocharov, Alexander
Baranova, Irina
Csako, Gyorgy
Eggerton, Thomas
Patterson, Amy
Remaley, Alan
Vishnyakova, Tatyana

<120> Scavenger Receptor B1 Targeting for the Treatment of Infection,
Sepsis and Inflammation

<130> 03514.115-PCT

<140> 10533103
<141> 2008-07-23

<150> 60/422,105
<151> 2002-10-30

<160> 14

<170> PatentIn version 3.2

<210> 1
<211> 21
<212> DNA
<213> Homo sapiens

<400> 1
gtcttcacca ccatggagaa g 21

<210> 2
<211> 25
<212> DNA
<213> Homo sapiens

<400> 2
gcttcaccac cttcttgatg tcatac 25

<210> 3
<211> 21
<212> DNA
<213> Homo sapiens

<400> 3
ccaccccaacg aaggcttctg c 21

<210> 4
<211> 19
<212> DNA
<213> Homo sapiens

<400> 4
ctgaatggcc tccttatcc 19

<210> 5
<211> 20
<212> DNA
<213> Homo sapiens

<400> 5
caactacaaa gcccttttg 20

<210> 6
<211> 20
<212> DNA
<213> Homo sapiens

<400> 6
cttggctgtt ctccatgaag 20

<210> 7
<211> 18
<212> DNA
<213> Homo sapiens

<400> 7
ctgaaagctc tccacctc 18

<210> 8
<211> 18
<212> DNA
<213> Homo sapiens

<400> 8
gtgctgatgt accagttg 18

<210> 9
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic construct

<400> 9

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu
1 5 10 15

Ala Phe

<210> 10
<211> 37
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic construct

<400> 10

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu
1 5 10 15

Ala Phe Pro Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys
20 25 30

Leu Lys Glu Ala Phe
35

<210> 11
<211> 37
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic construct

<220>
<221> MISC_FEATURE
<222> (1)..(37)
<223> All residues D-Amino Acid

<400> 11

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu
1 5 10 15

Ala Phe Pro Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys
20 25 30

Leu Lys Glu Ala Phe
35

<210> 12
<211> 37
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic construct

<220>
<221> MISC_FEATURE

<222> (1)...(37)

<223> All Ala residues are D-Amino Acids

<400> 12

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu
1 5 10 15

Ala Phe Pro Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys
20 25 30

Leu Lys Glu Ala Phe
35

<210> 13

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic construct

<220>

<221> MISC_FEATURE

<222> (1)...(37)

<223> All Tyr and Val are D-Amino Acid Residues

<400> 13

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu
1 5 10 15

Ala Phe Pro Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys
20 25 30

Leu Lys Glu Ala Phe
35

<210> 14

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic construct

<220>

<221> MISC_FEATURE

<222> (1)...(37)

<223> All Asp, Lys and Ala are D-Amino Acid Residues

<400> 14

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu

1 5 10

15

Ala Phe Pro Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys

20 25

30

Leu Lys Glu Ala Phe

35